Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 2
1988 2
1989 1
1991 2
1992 2
1993 2
1994 7
1995 4
1996 5
1997 4
1998 2
1999 6
2000 8
2001 6
2002 6
2003 8
2004 4
2005 3
2006 4
2007 7
2008 6
2009 6
2010 4
2011 4
2012 4
2013 7
2014 12
2015 8
2016 11
2017 10
2018 9
2019 14
2020 15
2021 15
2022 12
Text availability
Article attribute
Article type
Publication date

Search Results

199 results
Results by year
Filters applied: . Clear all
Page 1
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.
Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Riesmeyer JS, Riddle MC, Rydén L, Xavier D, Atisso CM, Dyal L, Hall S, Rao-Melacini P, Wong G, Avezum A, Basile J, Chung N, Conget I, Cushman WC, Franek E, Hancu N, Hanefeld M, Holt S, Jansky P, Keltai M, Lanas F, Leiter LA, Lopez-Jaramillo P, Cardona Munoz EG, Pirags V, Pogosova N, Raubenheimer PJ, Shaw JE, Sheu WH, Temelkova-Kurktschiev T; REWIND Investigators. Gerstein HC, et al. Among authors: conget i. Lancet. 2019 Jul 13;394(10193):121-130. doi: 10.1016/S0140-6736(19)31149-3. Epub 2019 Jun 9. Lancet. 2019. PMID: 31189511 Clinical Trial.
Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial.
Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Botros FT, Riddle MC, Rydén L, Xavier D, Atisso CM, Dyal L, Hall S, Rao-Melacini P, Wong G, Avezum A, Basile J, Chung N, Conget I, Cushman WC, Franek E, Hancu N, Hanefeld M, Holt S, Jansky P, Keltai M, Lanas F, Leiter LA, Lopez-Jaramillo P, Cardona Munoz EG, Pirags V, Pogosova N, Raubenheimer PJ, Shaw JE, Sheu WH, Temelkova-Kurktschiev T; REWIND Investigators. Gerstein HC, et al. Among authors: conget i. Lancet. 2019 Jul 13;394(10193):131-138. doi: 10.1016/S0140-6736(19)31150-X. Epub 2019 Jun 9. Lancet. 2019. PMID: 31189509 Clinical Trial.
Effectiveness and Safety of Insulin Glargine 300 U/ml in Comparison with Insulin Degludec 100 U/ml Evaluated with Continuous Glucose Monitoring in Adults with Type 1 Diabetes and Suboptimal Glycemic Control in Routine Clinical Practice: The OneCARE Study.
Conget I, Mangas MÁ, Morales C, Caro J, Giménez M, Borrell M, Delgado E. Conget I, et al. Diabetes Ther. 2021 Nov;12(11):2993-3009. doi: 10.1007/s13300-021-01153-4. Epub 2021 Oct 2. Diabetes Ther. 2021. PMID: 34599749 Free PMC article.
The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial.
Gerstein HC, Hart R, Colhoun HM, Diaz R, Lakshmanan M, Botros FT, Probstfield J, Riddle MC, Rydén L, Atisso CM, Dyal L, Hall S, Avezum A, Basile J, Conget I, Cushman WC, Hancu N, Hanefeld M, Jansky P, Keltai M, Lanas F, Leiter LA, Lopez-Jaramillo P, Muñoz EGC, Pogosova N, Raubenheimer PJ, Shaw JE, Sheu WH, Temelkova-Kurktschiev T. Gerstein HC, et al. Among authors: conget i. Lancet Diabetes Endocrinol. 2020 Feb;8(2):106-114. doi: 10.1016/S2213-8587(19)30423-1. Epub 2020 Jan 7. Lancet Diabetes Endocrinol. 2020. PMID: 31924562 Clinical Trial.
Erectile function in men with type 2 diabetes treated with dulaglutide: an exploratory analysis of the REWIND placebo-controlled randomised trial.
Bajaj HS, Gerstein HC, Rao-Melacini P, Basile J, Colhoun H, Conget I, Cushman WC, Dagenais GR, Franek E, Hanefeld M, Keltai M, Lakshmanan M, Lanas F, Leiter LA, Lopez-Jaramillo P, Pirags V, Pogosova N, Probstfield J, Raubenheimer P, Ryden L, Shaw JE, Sheu WH, Xavier D. Bajaj HS, et al. Among authors: conget i. Lancet Diabetes Endocrinol. 2021 Aug;9(8):484-490. doi: 10.1016/S2213-8587(21)00115-7. Epub 2021 Jun 18. Lancet Diabetes Endocrinol. 2021. PMID: 34153269 Clinical Trial.
Priapism Associated With Cabergoline In A Young Adult.
Mesa A, Conget I, Viñals C. Mesa A, et al. Among authors: conget i. Endocrinol Diabetes Nutr (Engl Ed). 2021 Feb;68(2):139-140. doi: 10.1016/j.endinu.2020.01.008. Epub 2020 May 10. Endocrinol Diabetes Nutr (Engl Ed). 2021. PMID: 32402771 English, Spanish. No abstract available.
Dulaglutide and incident atrial fibrillation or flutter in patients with type 2 diabetes: A post hoc analysis from the REWIND randomized trial.
Raubenheimer PJ, Cushman WC, Avezum A, Basile J, Conget I, Dagenais G, Hoover A, Jansky P, Lanas F, Leiter LA, Lopez-Jaramillo P, Pogosova N, Probstfield J, Rao-Melacini P, Rydén L, Sheu WH, Temelkova-Kurktschiev T, C Gerstein H. Raubenheimer PJ, et al. Among authors: conget i. Diabetes Obes Metab. 2022 Apr;24(4):704-712. doi: 10.1111/dom.14634. Epub 2022 Jan 24. Diabetes Obes Metab. 2022. PMID: 34984808 Clinical Trial.
Profiling intra-patient type I diabetes behaviors.
Contreras I, Quirós C, Giménez M, Conget I, Vehi J. Contreras I, et al. Among authors: conget i. Comput Methods Programs Biomed. 2016 Nov;136:131-41. doi: 10.1016/j.cmpb.2016.08.022. Epub 2016 Sep 1. Comput Methods Programs Biomed. 2016. PMID: 27686710
199 results